Scalper1 News
Biotech Agios Pharmaceuticals (AGIO) continued its selloff Monday as Canaccord Genuity lowered its price target based on skepticism about one of its cancer drugs. Agios stock dropped 10% Friday on AG-221 clinical-trial results, though investment bank Cowen & Co. said in a research report that the numbers were misinterpreted. In his report Monday, Canaccord analyst John Newman agreed with that, but focused his concern on a different project Scalper1 News
Scalper1 News